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Introduction 
Breast cancer patients face complicated therapeutic decisions, with innumerable factors affecting 
these choices. Prior data have suggested that patients in the curative setting are willing to accept 
toxicity of adjuvant therapy for a small gain in survival[1,2]. However, the expected benefit and 
toxicity associated with a particular treatment is generally presented to patients based on non-
individualized data derived from large populations in clinical trials. The advent of 
pharmacogenomic biomarkers has made it possible to refine individual risk and benefit profiles. 
Our prior work identified single nucleotide polymorphism (SNP) biomarkers that predicted an 
increased risk of anthracycline induced congestive heart failure (CHF) and taxane induced 
peripheral neuropathy (PN)[3,4] , both commonly used chemotherapy classes in early stage 
breast cancer. However, it is not clear if, and to what degree, the individual shift of risk to benefit 
ratio predicted by biomarkers is relevant to treatment decisions made by patients. While there are 
rigorous standards applied to statistical significance and validation methodology, the approach to 
determine clinical relevance, especially for toxicity markers, is less than clear.  
Determining the clinical relevance of biomarker information on treatment decision making is 
complicated. The risk of each of a multitude of toxicities is variable at the individual level, and 
the impact this will have on decision-making depends on what other options are available with 
competing risks and benefits. Choice-based conjoint (CBC) analysis is a statistical technique that 
can be used in health outcomes research to determine how people value the features that make up 
a decision, in order to decide the most influential combination of factors. By estimating the 
relative importance of different characteristics, the impact of a specific factor on the ultimate 
decision can be observed[5-7]. A similar model was previously used to predict the influence of 
possible biomarkers in the metastatic setting and found that breast cancer patients would opt for 
treatment with a small likelihood of benefit despite risk of toxicity[8]. 
Herein, we report a CBC analysis approach to determine whether pharmacogenomic biomarker 
information influences a patient’s choice of therapy in the curative setting with conventional 
regimens. Using the profiles of common anthracycline and taxane-based regimens, we sought out 
to quantify the relative influence of changing degrees of benefit and toxicity risk on treatment 
choice for patients with HER2 negative, early stage breast cancer receiving chemotherapy with 
curative intent. Further, we sought to determine whether these results are affected by 
hypothetical biomarker information and whether validated biomarkers would result in a change 
in preferred therapeutic regimen. 
Methods 
Survey 
With the objective of deriving patient preferences using stated influence and CBC analysis, an 
online survey was developed incorporating a series of trade-offs to determine which combination 
of attributes had the greatest influence on choice. The survey asked whether patients had any 
prior experience with CHF or PN.  The grade of toxicity was assessed by patient reported 
symptoms as none, mild, moderate or severe (see online resource Methods for exact 
descriptions). Patients were asked whether prior experience with CHF or PN would have an 
impact on the decision to take a similar treatment in the future. Most of the survey was CBC-
based and presented 12 pairs of hypothetical treatment choices (example in online resource 
Figure S1). Each pair was based on benefit and risk attributes of common chemotherapy 
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regimens used in the adjuvant setting for early stage breast cancer: a non-taxane regimen, 
doxorubicin and cyclophosphamide (AC); a non-anthracycline regimen, docetaxel and 
cyclophosphamide (TC); and two anthracycline plus taxane regimens, doxorubicin and 
cyclophosphamide followed by paclitaxel (AC-T), and docetaxel, doxorubicin, and 
cyclophosphamide (TAC) (Table 1). The “base case” likelihood ranges used for benefit and 
toxicity were based upon published clinical trials[9-13]. The hypothetical case combinations 
were not meant to be exact likelihoods of the risk and benefit, but rather a reasonable depiction 
through which the degree of change and therefore the influence on decisions could be derived. 
To prevent bias, respondents were not given the names of the chemotherapy drugs represented. 
Possible choices included variations in level of benefit with a relative risk reduction for recurrent 
disease ranging from 20% to 50%. The benefit levels were customized based on the respondent’s 
perception of their individual risk of recurrence without chemotherapy, expressed as 10%, 20%, 
30%, or 40%. Those who perceived a risk “greater than 40%” were given 40% as a starting 
point. For each survey item, respondents were reminded of their starting perceived risk of 
recurrence, then given a choice between two treatment combinations described as further 
reducing their risk in terms of lifetime percentage of recurrence. Visual representation of these 
percentages was also provided (see online reference Figure S1). Combinations also described 
the likelihood of toxicities, including PN (likelihood range of 0%-60% with varied degrees of 
severity and duration) and CHF (likelihood range of 0%-10%). The risks of each toxicity and the 
likelihood of benefit were variably altered from the original base cases to mimic personalized 
risk provided by biomarkers. For each scenario, respondents were given the choice not to take 
chemotherapy. 
The survey was distributed online in September 2012 and January 2013 to eligible patients with 
early stage, HER2 negative breast cancer who had received chemotherapy within the prior 8 
years. Ongoing endocrine therapy was allowed. All patients had received prior therapy and 
therefore it is acknowledged that their opinions on chemotherapy choices may be biased by prior 
experiences. For the purposes of this study, the post-treatment population was chosen given the 
easier and immediate access to large numbers of patients. The survey was dispersed by a non-
profit patient support organization, Living Beyond Breast Cancer (LBBC), and an online data 
collection company, Research Now. LBBC participants were not compensated. Research Now 
participants received points. Informed consent was obtained and anonymity was protected. 
Statistical Analysis 
The primary objective of the analysis was to demonstrate that changes in toxicity risk would 
significantly alter patients’ therapeutic decisions. The percentage of self-reported demographic 
and disease related characteristics were reported. The percentage of respondents whose prior 
experience with toxicity influenced their future choice of treatment regimen was also reported. 
CBC analysis was applied to the survey data. Statistical analysis of the percentage preference 
share for each level of benefit and toxicity tested was performed using Sawtooth Software, 
utilizing a hierarchical Bayesian routine and the statistical software R version 3.3.0[14]. 
Confidence intervals were also calculated using the statistical software R (see online resource 
Methods). Subgroup analysis was performed based on the variables of perceived risk of 
recurrence, prior treatment setting, survey group, and prior experience with PN. 
The survey itself did not refer to biomarkers. Hypothetical biomarkers were modeled to 
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determine shifts in benefit and toxicity that would be necessary to change treatment selection 
using software R. Comparing relative preference shares between two sets of risk and benefit 
levels allowed for the prediction of biomarker influence, with greater differences indicating more 
influence. Once preference shares at different risk levels were determined, a linear regression 
model was fitted between the preference share and risk of toxicity. The fitted model was used to 
determine preference share shifts for known risks of toxicities found in our prior studies of 
validated biomarkers for PN and CHF. In this model, it was assumed that the baseline risk of 
toxicity represented the total population risk without any genetic biomarker information. For PN, 
modeling was performed using our previously identified SNP predicting the development of 
common toxicity criteria (CTC) version 3.0 grade 2-4 PN (rs3125923)[4]. Odds ratios from the 
chemotherapy trials ECOG 5103 and ECOG 1199 were used[15,13] (see online resource Figure 
S2). For CHF, modeling was performed using our previously discovered SNP (rs28714259) 
predicting the development of any grade of CHF[3]. The odds ratios from two adjuvant 
chemotherapy trials were used, E1199 and BEATRICE[16,13] (see online resource Figure S2). 
Results 
Patient characteristics 
A total of 417 patients participated. Data from 362 surveys were collected through LBBC. Data 
from 55 surveys were collected through Research Now. Demographic information is presented in 
Table 2. All respondents had a history of early stage, HER2 negative breast cancer and exposure 
to chemotherapy in the prior 8 years. All patients had completed their prescribed chemotherapy 
and 37% (n=153) continued to take hormone therapy. Prior side effects experienced by patients 
are presented in Table 2. Most patients perceived that their risk of breast cancer recurrence 
without chemotherapy was “substantially greater than 40%” (58%; n = 241). 
Stated influence of prior toxicity 
Based on stated influence, CHF (all grades) had the greatest impact on choice, with 35% (n = 6) 
of those with prior experience stating that they would be less likely to take a treatment with 
similar risk. Conversely, only 15% (n = 42) of patients with any grade of prior PN stated they 
would be less likely to take a similar treatment. However, of those with a history of self-reported 
severe PN (grade 3 by patient reporting) (n = 36), 47% reported they would be less likely to take 
a treatment that would cause the same degree of toxicity. For all tested side effects, a range of 
patients (20-35%) said they would be more likely to accept a similar treatment again, i.e. “know 
what it is like” (see online resource Table S1). 
Choice- based conjoint analysis 
CBC analysis indicated that a risk/benefit profile most similar to the non-anthracycline regimen 
TC had the greatest share of preference at 39%, compared to AC (27%), AC-T (19%), and TAC 
(14%). Given its overall preference, a profile similar to TC was used as the base case to 
determine shifts in preference when attribute levels were changed. When evaluating all attributes 
in a sensitivity analysis, recurrence risk reduction and the likelihood of PN caused the largest 
shift in preference (Figure 1). 
Subgroup analysis 
Respondents from LBBC and Resource Now were both predicted to prefer a non-anthracycline 
regimen (48.3% and 37.7% for TC, p = 0.09), as well as patients treated in a community or an 
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academic setting (39.0% and 39.2% for TC, p = 0.47). Patients who perceived a lower risk of 
recurrence had a significantly higher preference for a non-anthracycline regimen than those who 
perceived a high risk of recurrence (52% vs 36.3% for TC, p = 0.01). Patients with a higher 
perceived risk of recurrence shifted more preference toward a profile similar to the anthracycline 
plus taxane regimen AC-T (20.6% versus 10.1%, p = 0.01) (see online resource Table S2).   
Patients who previously experienced PN had a slightly higher preference for taxane containing 
regimens modeling a moderate risk of PN, and a significantly lower preference for a non-taxane 
containing regimen with zero risk of PN, compared to those who had not previously experienced 
PN. When the case scenario was changed to reflect a lower likelihood of PN, but described as 
severe and lifelong, patients were more likely to switch their preference to a non-taxane regimen. 
As shown in Table 3, this change was greatest in the respondents who had experienced prior PN, 
compared to those who had not (31.0% to 43.3% preference for AC in PN naïve patients, versus 
25.5% to 47.9% preference for AC in PN experienced patients).   
Biomarker modeling 
Given that it was most preferred, a profile similar to TC was used as the base case for biomarker 
analysis. As the likelihood of benefit from taxanes increased, the preference share for any 
taxane-based regimen increased. At a 20% recurrence risk reduction, 41.3% of patients preferred 
a taxane regimen, compared to 76.1% at a 50% recurrence risk reduction (see online resource 
Table S3). 
Preferences also changed based on variable risk of toxicity. As the likelihood of PN increased, 
the preference share for any taxane-containing regimen decreased (see online resource Figure 
S3). When using these data to model our previously identified SNP predicting grade 2-4 PN, the 
preference for a taxane based regimen dropped significantly when modeling the risk of being 
homozygous variant for the SNP (Table 4). 
Similarly, as the likelihood of CHF related to anthracyclines increased, the fraction choosing an 
anthracycline-containing regimen decreased (see online resource Figure S3).  When modeling 
our previously discovered SNP predicting the development of CHF, the odds ratios from two 
different adjuvant chemotherapy trials was used. While the OR increased from wild type to 
heterozygous variant in both trial cohorts, it decreased to zero when homozygous variant in the 
BEATRICE cohort. Overall, as risk for CHF increased, the preference for any anthracycline 
containing regimen decreased (Table 5). 
Discussion 
The risk to benefit ratio of chemotherapy regimens is derived from clinical trials and is 
applicable at the population level, but not necessarily to an individual patient. While much work 
remains to elucidate biomarkers that will further refine individual risk and benefit, it is important 
to determine what clinical relevance this will have on patient decision-making. We applied a 
CBC analysis on early stage, HER2 negative breast cancer patients who had received prior 
chemotherapy. The analysis sought to derive the importance of benefit versus risk of toxicity on 
treatment decision-making in the adjuvant setting for commonly used regimens with competing 
risk/benefit profiles. We modeled scenarios based on our prior discovery of SNPs that are 
significantly associated with the development of PN or CHF, to determine whether the 
knowledge of such biomarkers would impact hypothetical treatment choices. 
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Prior studies in both the adjuvant and metastatic setting have concluded that when considering 
the toxicity risk versus clinical benefit of adjuvant chemotherapy, breast cancer patients are more 
likely to accept a risk of toxicity for a relatively small benefit[8,2,17,18]. However, few studies 
have evaluated the risk and benefit profiles of current therapies used with curative intent in the 
adjuvant setting. In a systematic review by Duric et al. evaluating patient preferences for 
adjuvant chemotherapy, four trials from the 1990s were evaluated using early generation 
regimens [2]. A more recent CBC analysis of breast cancer patients by Beusterien et al. modeled 
side effects and degrees of benefit; however, this included patients in the metastatic setting and 
did not evaluate the risk of severe, lifelong PN or CHF[18]. A study by Smith and colleagues 
evaluated patient preference for the profiles of paclitaxel and capecitabine using conjoint 
analysis, however this was performed in the metastatic setting[8]. Our study is one of the first to 
highlight patient preferences using profiles of current therapies used in the curative setting, 
focusing on the risk of life- altering toxicities like severe PN and CHF, and the first to examine 
preferences with risk profiles where validated biomarkers impact treatment decisions. In contrast 
to prior literature, our study found that patients accepted a higher likelihood of disease 
recurrence when faced with increased risk for severe toxicities. 
In our analysis, personal experience affected treatment choices. Based on stated influence, the 
majority of patients who had experienced mild/moderate PN in the past would not be impacted 
by this when making treatment choices. In fact, a proportion of patients with prior CHF or PN 
would actually be more likely to take a similar treatment. However, severity of PN had a 
significant influence, with nearly half of patients who had experienced prior severe PN reporting 
they would be less likely to consider a similar treatment. CBC analysis showed similar results, 
with those who had previously experienced PN displaying a slightly higher preference for 
taxane-containing regimens than those with no prior PN. It is surprising that patients who 
suffered from toxicity would accept that toxicity again, but perhaps this reflects a familiarity and 
tolerability. However, patients who previously experienced PN were less likely to accept a 
regimen that would cause severe or lifelong PN, perhaps reflecting a population with a more 
nuanced understanding of the variability and impact of this toxicity.  
Based on CBC analysis, the most preferred regimen was a non-anthracycline regimen similar to 
TC. As expected, the incremental gain in benefit in terms of reduced risk of recurrence had a 
substantial impact on the selected regimen. Further, unlike prior studies evaluating older 
regimens or those in the metastatic setting, the preference for a regimen substantially decreased 
as the likelihood of each toxicity increased. This change was most dramatic for CHF. When PN 
was estimated to be less likely but severe and irreversible, patients dramatically shifted 
preference to a non-taxane regimen.  
Prior data have demonstrated that a patient’s risk of therapy-induced toxicity can vary based on 
germline genotype[3,4]. When modeling the likelihood of PN after the risk associated with the 
most significant SNP in our prior genome-wide association study, patients were less likely to 
choose a taxane regimen if the likelihood of PN was similar to being homozygous variant for the 
SNP. Similarly, patients were less likely to choose an anthracycline regimen when their risk 
mimicked being homozygous variant for our previously identified SNP predicting CHF in the 
E1199 cohort. In the BEATRICE cohort, while risk of CHF increased for patients who were 
heterozygous, no CHF events were observed in homozygous variant patients, likely due to the 
relative infrequency of CHF events overall. Knowledge of changing risk profiles that might be 
provided by biomarkers appears to greatly impact treatment decisions.   
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An inherent weakness to the CBC analysis is that we do not know how a patient’s discussion 
with a physician might influence choice. It is impossible to know whether a patient would make 
the same choice when faced with an actual therapeutic decision compared to the hypothetical 
scenarios. There are many factors involved in treatment decisions at the individual level that 
cannot be captured by survey analysis. However, aggregating responses from a larger group with 
prior chemotherapy experience allows us to summarize the value of a certain benefit or toxicity 
and identify inflection points where the group would begin to shift therapeutic decision making. 
In addition, a weakness of our study is that we are missing the preferences of patients who have 
not yet undergone treatment with chemotherapy, or patients for whom chemotherapy did not 
have the desired benefit. The responses are most certainly biased by individual experiences, and 
the respondents in our study may be more likely to choose benefit over toxicity given that none 
had recurred at the time of the survey. However, our interest was in patients with real life 
experience making such decisions, who were also removed from that experience and more likely 
to provide less emotionally driven responses to treatment decisions. In addition, we were 
ultimately interested in whether the additional information provided by biomarkers would alter 
the decisions of patients who are already aware of the consequences of chemotherapy toxicity. 
It is notable that most patients perceived a high risk of recurrent disease greater than 40%. We 
did not have access to medical records and it is unclear if patients over-estimated their risk, or 
how they came up with this number. In addition, given that the patients in this study had not 
experienced a recurrence of their breast cancer, it is possible they placed additional value in 
whatever therapy they had previously received, whether that included chemotherapy or not. 
Importantly, despite the perception of a high likelihood of recurrence, these patients still 
exhibited substantial concerns about toxicity risks. This further highlights the discrepancy of 
these data with prior studies that suggest patients will accept significant toxicity for a small gain 
in benefit and calls for additional validation studies. It also highlights the contrast of clinically 
impactful and potentially irreversible toxicities modeled here with current regimens used in the 
curative setting.      
This study demonstrates that patients consider many variables when making treatment choices, 
including perceived disease risk, prior experience with toxicity, added benefit, and both the 
likelihood and severity of toxicity. It should not be assumed that patients are accepting of a 
certain level of toxicity for small gains in benefit in the curative setting. In addition, the data 
presented here support that decision-making is affected by information that biomarkers could 
provide. While improvements in personalized medicine have the capacity to empower patients, 
some will be overwhelmed with options. Analyses such as these can provide inflection points 
where the majority of a patient’s peers would shift therapy and can serve as a guide to the 
“preferred” regimen. It is exciting that genotypic markers continue to be discovered; however, 
this information must be clinically useful to patients to be a meaningful part of treatment 
discussions. While there is currently no accepted definition for clinical utility, we propose that 
future studies of biomarker significance include measures of clinical relevance. Future directions 
include similar analyses at different time points in order to determine the influence of time from 
treatment on choice, as well as prospective validation of both toxicity biomarkers and the clinical 
influence of these biomarkers, including the results presented here. As information continues to 
emerge, involvement of patients in dialogue surrounding their treatment choices will remain of 
the utmost importance. 
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Figure 1.  Sensitivity analysis showing change in preference share of responders at varied levels of attributes. A regimen with a 
profile similar to TC (docetaxel and cyclophosphamide) was used as the starting base case.  The largest shifts in preference were 
seen with alterations in risk reduction benefit and in peripheral neuropathy likelihood.  However, large shifts were also seen with 
duration and severity of PN (peripheral neuropathy), with a large drop when PN was severe and lifelong.  In addition, preference 
dropped steeply as the risk of CHF (congestive heart failure) approached 10%. 
 
 
 
Table 1 Base case regimens used in conjoint analysis survey 
Regimen* AC  TC AC-T TAC 
Likelihood of benefit 
(%)** 
27 35 43 43 
PNa likelihood (%) 0 15 27 15 
PN severity, duration none Moderate, 1 yr Moderate, 1 yr Moderate, 1 yr 
CHFb likelihood (%) 1.5 0 1.5 1.5 
*AC – doxorubicin/cyclophosphamide; TC – docetaxel/cyclophosphamide; AC-T – doxorubicin/cyclophosphamide followed by 
paclitaxel; TAC – docetaxel, doxorubicin, cyclophosphamide 
**in terms of relative recurrence risk reduction 
a – peripheral neuropathy; b – congestive heart failure 
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Table 2 Patient and disease related characteristics 
Variable Percent of respondents (N = 417) 
(%) 
Ethnicity 
    Caucasian 
    African American 
    Hispanic 
    Other 
 
88 
5 
4 
3 
Age 
    < 50 yrs old 
    ≥ 50 yrs old 
 
35 
65 
Married 70 
Children 
      Children < 22 yrs old 
      All children ≥ 22 yrs old 
      No children 
      Prefer to not answer 
 
29 
45 
25 
1 
Highest education level 
      High school graduate 
      Associates degree 
      Bachelor’s degree 
      Post-graduate degree 
 
24 
9 
39 
28 
Annual household income (dollars) 
      <50,000 
       50-100,0000 
       >100,000 
       Declined to respond 
 
14 
36 
29 
21 
Time since breast cancer diagnosis 
       < 1 yr 
       1 – 5 yrs 
       5 – 8 yrs 
 
10 
61 
29 
Prior treatment setting 
      Academic center 
      Community/private practice 
 
32 
68 
Prior therapy in addition to surgery and 
chemotherapy 
      Hormone therapy 
      Radiation 
 
 
51 
71 
Prior chemotherapy side effects 
      Fatigue 
      Hair loss 
      Nausea/vomiting 
      Diarrhea 
      Hand foot syndrome 
 
86 
90 
50 
23 
14 
12 
 
      Cognitive problems 
      Anxiety/depression 
      Peripheral neuropathy 
      Neutropenia 
      Infection 
      Congestive heart failure 
71 
55 
66 
60 
20 
4 
Current quality of life* 
         0 – 4 
         5 – 7  
         8 – 10  
 
4 
28 
68 
Perceived risk of cancer recurrence without 
chemotherapy** 
      10% 
      20% 
      30% 
      40% 
      > 40% 
 
 
5 
13 
12 
12 
58 
* 0 = as bad as it can be, 10 = as good as it can be 
** Patients reporting a perceived risk of recurrence >40% used 40% as their starting point for the remainder of the survey 
 
Table 3 Choice of regimen by percent of preference share when altering risk and duration of peripheral neuropathy (PN), 
comparing those are were PN naïve with those who have experience with prior PN 
Regimen* 
Peripheral neuropathy naïve    
(n = 140) (%) 
Prior experience with peripheral 
neuropathy (n = 277) (%) 
  Base casea  Severe PNb    P**  Base case  Severe PN     P 
 AC profile  31.0 43.3  < 0.001  25.5 47.9  < 0.001
 TC profile  37.4 25.1  < 0.001  40.0 23.2  < 0.001
 AC -> T profile  17.3 22.1 0.06  19.4 19.4 0.5 
 TAC profile  12.8 7.8  < 0.001  14.5 8.5  < 0.001
 None  1.5 1.7 0.28  0.6 1.1  < 0.001
*AC – doxorubicin/cyclophosphamide; TC – docetaxel/cyclophosphamide; AC-T – doxorubicin/cyclophosphamide followed by paclitaxel; TAC 
– docetaxel, doxorubicin, cyclophosphamide 
**p – Bayesian p value 
a – base case represents risk of moderate peripheral neuropathy with a likelihood of 15%, b – severe PN case represents risk of severe and 
lifelong PN with a likelihood of 5% 
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Table 4 Shift in percentage of preference for taxane containing regimens with changing degrees of peripheral neuropathy risk 
modeling the known biomarker rs3125923. 
Dataset Genotype* Frequency 
of PNa 
Preference 
of any Tb 
(%) 
95% CI Preference 
of ACc 
(%) 
95% CId 
 
E5103 
WT/WT 20% 74.2 71.7- 76.7 25.0 22.6- 27.3 
WT/Var 27% 68.2 65.8- 70.1 30.9 28.5- 33.2 
Var/Var 35% 61.4 58.9- 63.9 37.6 35.2- 40.0 
 
E1199 
 
WT/WT 17% 74.5 72.0- 76.9 24.7 22.3- 27.1 
WT/Var 19% 72.5 70.0- 74.4 26.6 24.3- 29.0 
Var/Var 82% 10.3 5.0 – 15.5 88.1 83.0- 93.1 
  *WT/WT – homozygous wild type; WT/Var – heterozygous; Var/Var – homozygous variant 
a  – peripheral neuropathy; b – any taxane containing regimen; c  – doxorubicin/cyclophosphamide; d – confidence interval 
 
 
 
Table 5 Shift in percentage of preference for anthracycline containing regimens with changing degrees of congestive heart failure 
risk modeling the known biomarker rs28714259. 
    
Dataset Genotype* Frequency 
of CHFa 
Preference 
of any 
Ab(%) 
95% CI Preference 
of TCc  
(%) 
95% CId 
 
E1199 
WT/WT 1.2% 61.4 59.0- 63.8 37.7 35.3- 40.0 
WT/Var 2.3% 56.3 53.9- 58.6 42.8 40.4- 45.1 
Var/Var 3.4% 50.6 47.7- 53.5 48.3 45.4- 51.2 
 
BEATRICE WT/WT 2.4% 61.7 59.3- 64.1 37.5 35.1- 39.8 
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 WT/Var 5.4% 54.4 52.0- 56.9 44.6 42.1- 47.0 
Var/Var 0.0% 67.5 64.5- 70.6 31.7 28.6- 34.7 
 *WT/WT – homozygous wild type; WT/Var – heterozygous; Var/Var – homozygous variant 
a  – congestive heart failure; b – any anthracycline containing regimen; c  – docetaxel/cyclophosphamide; d – confidence interval 
 
 
 
 
